BioLineRx (BLRX) Fundamental Analysis: Revenue, Earnings & Valuation

7.95 / 10

Outperform

Fundamentally, BLRX is rated Outperform with an 8/10 quality score. Strong Asset‑MV, Revenue‑MV and Profit‑MV factors boost its profile, while Cash‑MV is modest. Risks stem from weak current‑asset turnover and adverse income‑tax‑to‑profit ratio, tempering the upside.

Analysis Checks(7/10)

Revenue-MV

Value-2.20

Score2/3

Weight20.42%

1M Return8.05%

Inventory turnover ratio

Value0.07

Score2/3

Weight-1.07%

1M Return-0.56%

Gross profit margin (%)

Value80.73

Score0/3

Weight-8.47%

1M Return-5.42%

Profit-MV

Value-0.85

Score3/3

Weight32.59%

1M Return9.40%

Income tax / Total profit (%)

Value-5.52

Score1/3

Weight0.41%

1M Return0.21%

Current assets turnover ratio

Value0.04

Score0/3

Weight-3.10%

1M Return-1.61%

Fixed assets turnover ratio

Value3.56

Score2/3

Weight0.02%

1M Return0.01%

Cost of sales ratio (%)

Value19.27

Score2/3

Weight-6.81%

1M Return-3.62%

Asset-MV

Value-0.48

Score3/3

Weight49.73%

1M Return15.70%

Cash-MV

Value-0.09

Score2/3

Weight16.28%

1M Return6.19%

Is BLRX undervalued or overvalued?

BLRX scores 7.95/10 on fundamentals and holds a Discounted valuation at present. Backed by its -6.38% ROE, -171.69% net margin, -8.85 P/E ratio, 0.45 P/B ratio, and 100.00% earnings growth, these metrics solidify its Outperform investment rating.